IP Library Granted Patent US 10,611,759
Granted Patent B2
US 10,611,759 · App. 15/693,291 · Granted Apr 7, 2020

Glutaminase inhibitors

Inventors: Prashant K. Bhavar (Hyderabad, IN); Swaroop K. Vakkalanka (La Chaux-de-Fonds, CH); Srikant Viswanadha (Hyderabad, IN); Gayatri Swaroop Merikapudi (Hyderabad, IN); Govindarajulu Babu (Hyderabad, IN)
Assignee: RHIZEN PHARMACEUTICALS SA
C07D417/14A61K31/433A61K31/44A61K31/444A61K31/4439A61K31/4545A61K31/497A61K31/4965A61K31/501A61K31/505A61K31/506A61K45/06C07D213/75C07D239/42C07D241/20C07D285/135C07D401/04C07D401/12C07D417/06C07D417/08Y02A50/422
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,611,759
App. No.
15/693,291
Granted
Apr 7, 2020
Kind
B2
Abstract

The present disclosure provides compounds of formula (I) to (III) as glutaminase inhibitors, methods of preparing them, pharmaceutical compositions containing them and methods of treatment, prevention and/or amelioration of diseases or disorders involving glutamine.

Claims (99)

1. A compound of formula (II) or (III)

or a tautomer thereof, prodrug thereof, N-oxide thereof, stereoisomer thereof, pharmaceutically acceptable ester thereof or pharmaceutically acceptable salt thereof, wherein

L is L 1 -L 2 -L 3 -; wherein

L 1 is absent;

L 3 is absent or —CH 2 —; and

L 2 is

wherein

(i) D is CH and E is N or (ii) D is N and E is CH;

each of R a , R b , R c , R d , R e , R f , R g and R h is hydrogen;

the sum of s and t is 2 and the sum of u and v is 2, or the sum of s and t is 3 and the sum of u and v is 1;

R 1 is substituted or unsubstituted phenyl, or substituted or unsubstituted pyridinyl;

R 2 is substituted or unsubstituted phenyl, substituted or unsubstituted pyridinyl, substituted or unsubstituted pyridazinyl, substituted or unsubstituted quinolinyl, or substituted or unsubstituted indolyl;

each occurrence of R x , and R y is independently selected from hydrogen, and substituted or unsubstituted alkyl; and

R 3 is hydrogen, halogen, substituted or unsubstituted C 1-3 alkyl, nitro, amino, substituted or unsubstituted C 1-6 alkoxy, or substituted or unsubstituted C 1-6 alkylamino;

wherein the term “substituted” refers to substitution with one or more of the following substituents which may be the same or different and are independently selected from hydroxy, halogen, cyano, C 1-6 alkyl optionally substituted with hydroxyl or halogen, C 1-8 alkoxy optionally substituted with halogen, heterocyclic ring optionally substituted with halogen, —S(O) 2 R x and —N(R x )SO 2 R y , wherein R x is hydrogen, and R y is hydrogen or C 1-6 alkyl.

2. A compound of claim 1 , wherein R 3 is hydrogen, halogen or substituted or unsubstituted C 1-3 alkyl.

3. A compound of claim 1 , wherein R 3 is hydrogen, fluorine or methyl.

4. A compound of claim 1 , wherein

(i) R 1 is substituted or unsubstituted phenyl and R 2 is substituted or unsubstituted phenyl, substituted or unsubstituted pyridinyl, substituted or unsubstituted pyridazinyl, substituted or unsubstituted quinolinyl, or substituted or unsubstituted indolyl;

(ii) R 1 is substituted or unsubstituted pyridinyl and R 2 is substituted or unsubstituted phenyl;

(iii) both R 1 and R 2 are substituted or unsubstituted phenyl; or

(iv) both R 1 and R 2 are, independently, substituted or unsubstituted pyridinyl or substituted or unsubstituted pyridazinyl.

5. A compound of claim 1 , wherein R 1 is

and R 2 is

6. A compound of claim 1 , wherein R x and R y are each, independently, hydrogen or —CH 2 OH.

7. A compound of claim 1 , selected from:

2-(Pyridin-2-yl)-N-(5-(1-(6-(2-(3-(trifluoromethoxy)phenyl)acetamido)pyridin-3-yl) piperidin-4-yl)-1,3,4-thiadiazol-2-yl)acetamide;

(RS)-2-(Pyridin-2-yl)-N-(5-(1-(6-(2-(3-(trifluoromethoxy)phenyl)acetamido)pyridin-3-yl) piperidin-3-yl)-1,3,4-thiadiazol-2-yl)acetamide;

(R)-2-(Pyridin-2-yl)-N-(5-(1-(6-(2-(3-(trifluoromethoxy)phenyl)acetamido) pyridin-3-yl) piperidin-3-yl)-1,3,4-thiadiazol-2-yl)acetamide;

(S)-2-(Pyridin-2-yl)-N-(5-(1-(6-(2-(3-(trifluoromethoxy)phenyl)acetamido) pyridin-3-yl) piperidin-3-yl)-1,3,4-thiadiazol-2-yl)acetamide;

(RS)-2-(Pyridin-3-yl)-N-(5-(1-(6-(2-(3-(trifluoromethoxy)phenyl)acetamido)pyridin-3-yl) piperidin-3-yl)-1,3,4-thiadiazol-2-yl)acetamide;

(R)-2-(Pyridin-3-yl)-N-(5-(1-(6-(2-(3-(trifluoromethoxy)phenyl)acetamido) pyridin-3-yl) piperidin-3-yl)-1,3,4-thiadiazol-2-yl)acetamide;

(S)-2-(Pyridin-3-yl)-N-(5-(1-(6-(2-(3-(trifluoromethoxy)phenyl)acetamido) pyridin-3-yl) piperidin-3-yl)-1,3,4-thiadiazol-2-yl)acetamide;

2-(Pyridin-3-yl)-N-(5-(1-(6-(2-(3-(trifluoromethoxy)phenyl)acetamido)pyridin-3-yl) piperidin-4-yl)-1,3,4-thiadiazol-2-yl)acetamide;

2-(3-Cyanophenyl)-N-(5-(1-(6-(2-(3-(trifluoromethoxy)phenyl)acetamido)pyridin-3-yl)piperidin-4-yl)-1,3,4-thiadiazol-2-yl)acetamide;

2-(Pyridin-2-yl)-N-(5-(4-(5-(2-(3-(trifluoromethoxy)phenyl)acetamido)-1,3,4-thiadiazol-2-yl)piperidin-1-yl)pyridin-2-yl)acetamide;

2-(Pyridin-2-yl)-N-(5-(3-(5-(2-(3-(trifluoromethoxy)phenyl)acetamido)-1,3,4-thiadiazol-2-yl)piperidin-1-yl)pyridin-2-yl)acetamide;

2-(pyridin-2-yl)-N-(5-(1-(6-(2-(3-(trifluoromethoxy)phenyl)acetamido)pyridazin-3-yl) piperidin-4-yl)-1,3,4-thiadiazol-2-yl)acetamide;

2-(Pyridin-2-yl)-N-(5-(1-(6-(2-(3-(trifluoromethoxy)phenyl)acetamido)pyridazin-3-yl)piperidin-3-yl)-1,3,4-thiadiazol-2-yl)acetamide;

2-(Pyridin-3-yl)-N-(5-(1-(6-(2-(3-(trifluoromethoxy)phenyl)acetamido)pyridazin-3-yl)piperidin-4-yl)-1,3,4-thiadiazol-2-yl)acetamide;

2-(3-(Methylsulfonamido)phenyl)-N-(5-(1-(6-(2-(3-(trifluoromethoxy)phenyl) acetamido)pyridazin-3-yl)piperidin-4-yl)-1,3,4-thiadiazol-2-yl)acetamide;

2-(2-Chlorophenyl)-N-(6-(4-(5-(2-(pyridin-2-yl)acetamido)-1,3,4-thiadiazol-2-yl) piperidin-1-yl)pyridazin-3-yl)acetamide;

2-(2-Chlorophenyl)-N-(5-(1-(6-(2-(3-(trifluoromethoxy)phenyl)acetamido)pyridazin-3-yl)piperidin-3-yl)-1,3,4-thiadiazol-2-yl)acetamide;

2-(2-Fluorophenyl)-N-(6-(4-(5-(2-(pyridin-2-yl)acetamido)-1,3,4-thiadiazol-2-yl) piperidin-1-yl)pyridazin-3-yl)acetamide;

2-(Pyrazin-2-yl)-N-(5-(1-(6-(2-(3-(trifluoromethoxy)phenyl)acetamido)pyridazin-3-yl)piperidin-4-yl)-1,3,4-thiadiazol-2-yl)acetamide;

2-(Pyridin-2-yl)-N-(5-(1-(6-(2-(3-(trifluoromethoxy)phenyl)acetamido)pyridazin-3-yl)piperidin-4-yl)-1,3,4-thiadiazol-2-yl)acetamide dihydrochloride;

2-(Pyridin-2-yl)-N-(6-(4-(5-(2-(3-(trifluoromethoxy)phenyl)acetamido)-1,3,4-thiadiazol-2-yl)piperidin-1-yl)pyridazin-3-yl)acetamide;

2-(Pyridin-3-yl)-N-(6-(4-(5-(2-(3-(trifluoromethoxy)phenyl)acetamido)-1,3,4-thiadiazol-2-yl)piperidin-1-yl)pyridazin-3-yl)acetamide;

2-(Pyridin-3-yl)-N-(6-(4-(5-(2-(2,3,6-trifluorophenyl)acetamido)-1,3,4-thiadiazol-2-yl)piperidin-1-yl)pyridazin-3-yl)acetamide;

2-(Pyridin-2-yl)-N-(6-(4-(5-(2-(2,3,6-trifluorophenyl)acetamido)-1,3,4-thiadiazol-2-yl)piperidin-1-yl)pyridazin-3-yl)acetamide;

2-(2,3-Difluorophenyl)-N-(5-(1-(6-(2-(pyridin-2-yl)acetamido)pyridazin-3-yl)piperidin-4-yl)-1,3,4-thiadiazol-2-yl)acetamide;

2-(3,4-Difluorophenyl)-N-(5-(1-(6-(2-(pyridin-2-yl)acetamido)pyridazin-3-yl)piperidin-4-yl)-1,3,4-thiadiazol-2-yl)acetamide;

2-(2-Fluorophenyl)-N-(5-(1-(6-(2-(pyridin-2-yl)acetamido)pyridazin-3-yl)piperidin-4-yl)-1,3,4-thiadiazol-2-yl)acetamide;

2-(3-Fluorophenyl)-N-(5-(1-(6-(2-(pyridin-2-yl)acetamido)pyridazin-3-yl)piperidin-4-yl)-1,3,4-thiadiazol-2-yl)acetamide;

2-(4-Fluorophenyl)-N-(5-(1-(6-(2-(pyridin-2-yl)acetamido)pyridazin-3-yl)piperidin-4-yl)-1,3,4-thiadiazol-2-yl)acetamide;

2-(2-Methoxyphenyl)-N-(5-(1-(6-(2-(pyridin-2-yl)acetamido)pyridazin-3-yl)piperidin-4-yl)-1,3,4-thiadiazol-2-yl)acetamide;

2-(2-Chlorophenyl)-N-(5-(1-(6-(2-(pyridin-2-yl)acetamido)pyridazin-3-yl)piperidin-4-yl)-1,3,4-thiadiazol-2-yl)acetamide;

2-(5-Chloro-2-(trifluoromethyl)phenyl)-N-(5-(1-(6-(2-(pyridin-2-yl)acetamido) pyridazin-3-yl)piperidin-4-yl)-1,3,4-thiadiazol-2-yl)acetamide;

2-(4-Chlorophenyl)-N-(5-(1-(6-(2-(pyridin-2-yl)acetamido)pyridazin-3-yl)piperidin-4-yl)-1,3,4-thiadiazol-2-yl)acetamide;

2-(Quinolin-6-yl)-N-(5-(1-(6-(2-(3-(trifluoromethoxy)phenyl)acetamido)pyridazin-3-yl)piperidin-4-yl)-1,3,4-thiadiazol-2-yl)acetamide;

2-o-Tolyl-N-(5-(1-(6-(2-(3-(trifluoromethoxy)phenyl)acetamido)pyridazin-3-yl) piperidin-4-yl)-1,3,4-thiadiazol-2-yl)acetamide;

N-(6-(4-(5-(2-(1H-indol-3-yl)acetamido)-1,3,4-thiadiazol-2-yl)piperidin-1-yl) pyridazin-3-yl)-2-(3-(trifluoromethoxy)phenyl)acetamide;

2-(2-Fluorophenyl)-N-(6-(4-(5-(2-(pyrazin-2-yl)acetamido)-1,3,4-thiadiazol-2-yl) piperidin-1-yl)pyridazin-3-yl)acetamide;

2-(3-(Azetidin-1-yl)phenyl)-N-(5-(1-(6-(2-(3-(trifluoromethoxy)phenyl)acetamido) pyridazin-3-yl)piperidin-4-yl)-1,3,4-thiadiazol-2-yl)acetamide;

2-(3-Chlorophenyl)-N-(5-(1-(6-(2-(pyridin-2-yl)acetamido)pyridazin-3-yl)piperidin-4-yl)-1,3,4-thiadiazol-2-yl)acetamide;

3-Hydroxy-2-phenyl-N-(5-(1-(6-(2-(3-(trifluoromethoxy)phenyl)acetamido) pyridazin-3-yl)piperidin-4-yl)-1,3,4-thiadiazol-2-yl)propanamide;

(R)-2-hydroxy-2-phenyl-N-(5-(1-(6-(2-(3-(trifluoromethoxy)phenyl)acetamido) pyridazin-3-yl)piperidin-4-yl)-1,3,4-thiadiazol-2-yl)acetamide;

2-(3-(3-Fluoroazetidin-1-yl)phenyl)-N-(5-(1-(6-(2-(3-(trifluoromethoxy)phenyl) acetamido)pyridazin-3-yl)piperidin-4-yl)-1,3,4-thiadiazol-2-yl)acetamide;

2-(Pyridin-2-yl)-N-(5-((1-(6-(2-(3-(trifluoromethoxy)phenyl)acetamido)pyridazin-3-yl) piperidin-4-yl)methyl)-1,3,4-thiadiazol-2-yl)acetamide;

and pharmaceutically acceptable salts thereof.

8. A pharmaceutical composition comprising a compound of claim 1 and a pharmaceutically acceptable carrier.

9. The pharmaceutical composition of claim 8 , further comprising one or more additional therapeutic agents selected from anti-cancer agents, anti-inflammatory agents, immunosuppressive agents, steroids, non-steroidal anti-inflammatory agents, antihistamines, analgesics, and mixtures thereof.

10. A compound of claim 1 , wherein

(i) L 1 and L 3 are absent; or

(ii) L 1 is absent and L 3 is —CH 2 —.

11. A compound of claim 1 , wherein D is CH and E is N.

12. A compound of claim 1 , wherein L (L 1 -L 2 -L 3 ) is

13. A compound of claim 1 , wherein L 2 is

14. A compound of claim 1 , wherein L 2 is

15. A compound of formula (II) or (III)

or a tautomer thereof, prodrug thereof, N-oxide thereof, stereoisomer thereof, pharmaceutically acceptable ester thereof or pharmaceutically acceptable salt thereof, wherein

L is -L 1 -L 2 -L 3 -; wherein

L 1 is absent or —CH 2 —;

L 2 is piperidin-4-yl; and

L 3 is absent;

R 1 is selected from substituted or unsubstituted aryl and substituted or unsubstituted heteroaryl;

R 2 is pyridyl or pyradizin-3-yl;

each occurrence of R x and R y is independently selected from hydrogen and substituted or unsubstituted alkyl; and

R 3 is hydrogen, halogen, substituted or unsubstituted C 1-3 alkyl, nitro, amino, substituted or unsubstituted C 1-6 alkoxy, or substituted or unsubstituted C 1-6 alkylamino.

16. A method for the treatment of carcinoma of the kidney, carcinoma of the liver, or carcinoma of the lung, comprising the step of administering to a subject in need thereof an effective amount of compound of claim 1 .

17. The method of claim 16 , further comprising the step of administering simultaneously or sequentially to a subject in need thereof at least one other anti-cancer agent, anti-inflammatory agent, immunosuppressive agent, steroid, non-steroidal anti-inflammatory agent, antihistamine, analgesic, or a mixture thereof.

18. The method of claim 16 , wherein the subject suffers from carcinoma of the kidney.

19. The method of claim 16 , wherein the subject suffers from carcinoma of the liver.

20. The method of claim 16 , wherein the subject suffers from carcinoma of the lung.

21. A method for the treatment of carcinoma of the kidney, carcinoma of the liver, or carcinoma of the lung, comprising the step of administering to a subject in need thereof an effective amount of compound of claim 15 .

22. The method of claim 21 , further comprising the step of administering simultaneously or sequentially to a subject in need thereof at least one other anti-cancer agent, anti-inflammatory agent, immunosuppressive agent, steroid, non-steroidal anti-inflammatory agent, antihistamine, analgesic, or a mixture thereof.

23. The method of claim 21 , wherein the subject suffers from carcinoma of the kidney.

24. The method of claim 21 , wherein the subject suffers from carcinoma of the liver.

25. The method of claim 21 , wherein the subject suffers from carcinoma of the lung.

Assignments (2)
CHANGE OF ADDRESS Recorded Oct 6, 2021
From: RHIZEN PHARMACEUTICALS AG
To: RHIZEN PHARMACEUTICALS AG
Reel/Frame 057836/0286 →
CHANGE OF ADDRESS Recorded Mar 22, 2021
From: RHIZEN PHARMACEUTICALS SA
To: RHIZEN PHARMACEUTICALS SA
Reel/Frame 056775/0375 →
Priority Claims (9)
IN 36/CHE/2014 · Jan 6, 2014 · national
IN 39/CHE/2014 · Jan 6, 2014 · national
IN 2639/CHE/2014 · May 29, 2014 · national
IN 2647/CHE/2014 · May 29, 2014 · national
IN 2783/CHE/2014 · Jun 6, 2014 · national
IN 3525/CHE/2014 · Jul 18, 2014 · national
IN 3612/CHE/2014 · Jul 24, 2014 · national
IN 3613/CHE/2014 · Jul 24, 2014 · national
IN 5438/CHE/2014 · Oct 31, 2014 · national
Continuity (2)
Continuation 14769331
Related Publication 20180057487A1 · Mar 1, 2018